Fiocruz producing breast cancer drugs for the Brazilian health system

24 August 2020

Through its Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), the Oswaldo Cruz Foundation is now supplying trastuzumab to the Ministry of Health (MoH), which provides it to cancer patients free of cost through the Brazilian Public Health System (Portuguese name Sistema Único de Saúde, or SUS).

This is another cancer drug supplied by Bio-Manguinhos/Fiocruz, which introduced this line to its portfolio in 2020 (as well as rituximab, for the treatment of non-Hodgkin’s lymphomas, large B-cell lymphomas and follicular lymphomas, in addition to rheumatoid arthritis.

The active ingredient of Roche’s (ROG: SIX) blockbuster cancer drug Herceptin, trastuzumab is a monoclonal antibody indicated at the SUS to treat a subtype of breast cancer identified by the overexpression of the HER2 gene.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK